Nanobiotix S.A. (NASDAQ: NBTX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.58 | Insider Own | - | Shs Outstand | 50.60M | Perf Week | -4.57% |
| Market Cap | 1.82B | Forward P/E | - | EPS next Y | -0.49 | Insider Trans | - | Shs Float | 41.45M | Perf Month | -12.66% |
| Enterprise Value | 1.86B | PEG | - | EPS next Q | -0.17 | Inst Own | - | Short Float | 0.36% | Perf Quarter | -0.53% |
| Income | -28.00M | P/S | 55.01 | EPS this Y | 23.81% | Inst Trans | - | Short Ratio | 1.19 | Perf Half Y | 9.89% |
| Sales | 33.00M | P/B | - | EPS next Y | -11.67% | ROA | -35.36% | Short Interest | 149.22K | Perf YTD | 55.19% |
| Book/sh | -1.96 | P/C | 29.28 | EPS next 5Y | - | ROE | 31.23% | 52W High | 57.14 -37.21% | Perf Year | 268.38% |
| Cash/sh | 1.23 | P/FCF | - | EPS past 3/5Y | - | ROIC | -74.29% | 52W Low | 10.07 256.31% | Perf 3Y | 277.11% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 87.58% 61.54% | Gross Margin | - | Volatility | 4.38% 5.83% | Perf 5Y | 162.09% |
| Dividend TTM | - | EV/Sales | 56.50 | EPS Y/Y TTM | 62.77% | Oper. Margin | -36.49% | ATR (14) | 2.50 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.09 | Sales Y/Y TTM | 512.50% | Profit Margin | -80.83% | RSI (14) | 42.52 | Recom | 2.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.09 | EPS Q/Q | -39.38% | SMA20 | -9.21% | Beta | 0.78 | Target Price | 38.00 |
| Payout | 0.00% | Debt/Eq | 1.70 | Sales Q/Q | -91.43% | SMA50 | -8.85% | Rel Volume | 0.72 | Prev Close | 34.40 |
| Employees | 97 | LT Debt/Eq | -1.08 | Earnings | Sep 29 | SMA200 | 9.34% | Avg Volume | 137.66K | Price | 35.88 |
| IPO Date | Dec 11, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -7804.37% -87.85% | Net Debt/EBITDA | -3.53 | Volume | 99,772 | Change | 4.30% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jun-04-26 | Reiterated | Leerink Partners | Outperform | $26 → $46 |
| May-01-26 | Reiterated | UBS | Neutral | $30 |
| Nov-25-25 | Reiterated | Leerink Partners | $14 → $26 | |
| Sep-18-25 | Reiterated | Leerink Partners | $9.00 → $14 | |
| Aug-27-24 | Initiated | Guggenheim | Buy | $12 |
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 33 | 33 | -8 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | — | — | — | |
| Gross Profit | 33 | 33 | -8 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 23 | 23 | 22 | — | — | — | — | — | — | |
| Research and Development | 26 | 26 | 44 | — | — | — | — | — | — | |
| Other Operating Expense | -3 | -3 | 0 | — | — | — | — | — | — | |
| Operating Income | -13 | -12 | -74 | — | — | — | — | — | — | |
| Interest Expense | 12 | 12 | 9 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -3 | -3 | 9 | — | — | — | — | — | — | |
| Net Income Before Taxes | -28 | -27 | -74 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -28 | -27 | -74 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -28 | -27 | -74 | — | — | — | — | — | — | |
| Net Income | -28 | -27 | -74 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.58 | -0.56 | -1.56 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.58 | -0.56 | -1.56 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.58 | -0.56 | -1.56 | — | — | — | — | — | — | |
| EBITDA | -14 | -14 | -73 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 52.19 | 33.63 | -16.86 | — | — | — | — | — | — | |
| Gross Margin | 100.00 | 100.00 | 100.00 | — | — | — | — | — | — | |
| Operating Margin | -39.39 | -36.36 | 925.00 | — | — | — | — | — | — | |
| Net Margin | -84.85 | -81.82 | 925.00 | — | — | — | — | — | — | |
| Shares Outstanding | 48 | 48 | 47 | — | — | — | — | — | — | |
| Market Capitalization | 1,722 | 1,110 | 135 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |